Enhanced Compounds for Targeted Coronavirus Treatment

This invention relates to novel compounds and formulations for treating coronavirus-associated diseases, such as COVID-19, with improved targeted delivery, bioavailability, and reduced side effects.

The original patent disclosed compounds for treating coronavirus infections, but these compounds had limitations in terms of delivery, bioavailability, and side effects. The present inventive concept addresses these limitations by introducing pH-sensitive polymers, liposomal delivery vehicles, mucoadhesive polymers, and co-administration with immunomodulators, thereby enhancing targeted delivery to lung tissue, reducing side effects, and improving treatment outcomes.

The new compounds and formulations comprise a compound represented by Formula I, wherein R1-R6 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl. The compounds are formulated with pH-sensitive polymers to enhance targeted delivery to lung tissue, or with liposomal delivery vehicles to enhance bioavailability and reduce side effects. Additionally, the compounds may be administered via a nasal spray or inhaler to provide rapid onset of protection, or co-administered with an immunomodulator to enhance the immune response. The mucoadhesive polymer composition enhances retention in the respiratory tract, thereby improving treatment outcomes.

The new inventive concept is novel and non-obvious over the original patent as it introduces new formulations and delivery methods that overcome the limitations of the original compounds. The use of pH-sensitive polymers, liposomal delivery vehicles, mucoadhesive polymers, and co-administration with immunomodulators provides a significant improvement in targeted delivery, bioavailability, and treatment outcomes.

Alternative embodiments of the inventive concept may include the use of different polymers, delivery vehicles, or immunomodulators. Additionally, the compounds may be formulated with other excipients or additives to enhance their properties. The inventive concept may also be applied to other diseases or conditions, such as influenza or respiratory syncytial virus.

The enhanced compounds and formulations have significant commercial potential in the treatment of coronavirus-associated diseases, such as COVID-19. The target industries include pharmaceutical companies, biotechnology companies, and healthcare providers. The market potential is substantial, given the ongoing pandemic and the need for effective treatments.